射波刀SBRT治疗肝门区肝癌临床疗效观察

doi:10.3760/cma.j.issn.1004-4221.2018.02.011

摘要
图/表
参考文献()
相关文章 (15)
点击分布统计
下载分布统计

全文: PDF (0 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS) 背景资料

摘要目的评价射波刀在肝门区肿瘤治疗中的疗效及安全性。方法回顾分析2009—2015年间天津医科大学肿瘤医院收治的接受射波刀SBRT的 36例肝门区肝癌患者的病历资料。36例患者(37个病灶)的肿瘤直径为 15~55 mm (中位数30 mm),其中 20例患者(21个病灶)采用金标呼吸同步追踪技术,16例患者(16个病灶)采用椎体追踪技术。通过增强CT和(或) MRI评价肿瘤进展,Kaplan-Meier法计算LC、OS并Logrank检验和单因素分析。结果中位随访时间为12.7个月。术后1、2年LC率分别为90%、76%,术后 1年OS、PFS分别为63%、39%,中位OS、PFS时间分别为15.2、10.0个月。3级不良反应为11%。结论射波刀SBRT是肝门区肝癌的一种安全有效的治疗方式。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	邱鸣寒
	孟茂斌
	庄洪卿
	王欢欢
	董洋
	王境生
	袁智勇
	王平

关键词 ：肝肿瘤/立体定向放射疗法, 立体定向放射疗法, 射波刀, 治疗结果

Abstract：Objective To evaluate the efficacy and safety of CyberKnife stereotactic body radiation therapy (SBRT) in the treatment of hepatic hilar cancer. Methods A retrospective study was performed on the clinical data of 36 patients with hepatic hilar cancer who were admitted to our hospital and treated with CyberKnife SBRT from 2009 to 2015. In the 36 patients, 37 lesions were found with tumor diameters ranging from 1.5 to 5.5 mm (median diameter 3 cm). The Synchrony respiratory tracking system was used for 21 lesions in 20 patients, while the XSight spinal tracking system was used for 16 lesions in 16 patients. Local progression was evaluated based on contrast-enhanced computed tomography and/or magnetic resonance imaging. The Kaplan-Meier method was used to calculate local control (LC) and overall survival (OS) rates, and the log-rank test was used for survival comparison and univariate prognostic analysis. Results The median follow-up time was 12.7 months. The 1-and 2-year postoperative LC rates were 90% and 76%, respectively. The 1-year OS and progression-free survival (PFS) rates were 63% and 39%, respectively. The median OS and PFS times were 15.2 and 10 months, respectively. The incidence of grade 3 adverse reactions was 11%. Conclusions The CyberKnife SBRT is a safe and effective way to treat hepatic hilar cancer.

Key words： Liver neopiasins/stereotactic radiotherapy Stereotactic radiotherapy, CyberKnife Treatment outcome

收稿日期: 2017-01-13

通讯作者: 袁智勇,Email:zhiyong0524@163.com

引用本文:

邱鸣寒,孟茂斌,庄洪卿等. 射波刀SBRT治疗肝门区肝癌临床疗效观察[J]. 中华放射肿瘤学杂志, 2018, 27(2): 177-180.

Qiu Minghan,Meng Maobin,Zhuang Hongqing et al. Clinical efficacy of CyberKnife stereotactic body radiation therapy for hepatic hilar cancer[J]. Chinese Journal of Radiation Oncology, 2018, 27(2): 177-180.

链接本文:

http://journal12.magtechjournal.com/Jweb_fszlx/CN/10.3760/cma.j.issn.1004-4221.2018.02.011 或 http://journal12.magtechjournal.com/Jweb_fszlx/CN/Y2018/V27/I2/177

[1] Lai ECS,Fan ST,Lo CM,et al. Hepatic resection for hepatocellular carcinoma:an audit of 343 patients[J].Ann Surg,1995,221(3):291-298.DOI:10.1097/00000658-199503000-00012.
[2] Bartsch F,Heinrich S,Lang H.Limits of surgical resection for bile duct cancer[J].Viszeralmedizin,2015,31(3):189-193.DOI:10.1159/000433482.
[3] Crocetti L,de Baere T,Lencioni R.Quality improvement guidelines for radiofrequency ablation of liver tumours[J].Cardiovasc Intervent Radiol,2010,33(1):11-17.DOI:10.1007/s00270-009-9736-y.
[4] Kennedy AS,Sangro B.Nonsurgical treatment for localized hepatocellular carcinoma[J].Curr Oncol Rep,2014,16(3):373.DOI:10.1007/s11912-013-0373-x.
[5] Zamboglou C,MeBmer MB,Becker G,et al. Stereotactic radiotherapy in the liver hilum:basis for future studies[J].Strahlenther Onkol,2012,188(1):35-41.DOI:10.1007/s00066-011-0002-2.
[6] Chang BK,Timmerman RD.Stereotactic body radiation therapy:a comprehensive review[J].Am J Clin Oncol,2007,30(6):637-644.DOI:10.1097/COC.0b013e3180ca7cb1.
[7] Blechacz B,Gores GJ.Cholangiocarcinoma:advances in pathogenesis,diagnosis,and treatment[J].Hepatology,2008,48(1):308-321.DOI:10.1002/hep.22310.
[8] Teratani T,Yoshida H,Shiina S,et al. Radiofrequency ablation for hepatocellular carcinoma in so-called high-risk locations[J].Hepatology,2006,43(5):1101-1108.DOI:10.1002/hep.21164.
[9] Guo YJ,Zhang Y,Huang JJ,et al. Safety and efficacy of transarterial chemoembolization combined with CT-guided radiofrequency ablation for hepatocellular carcinoma adjacent to the hepatic hilum within Milan criteria[J].J Vasc Interv Radiol,2016,27(4):487-495.DOI:10.1016/j.jvir.2016.01.002.
[10] Kopek N,Holt MI,Hansen AT,et al. Stereotactic body radiotherapy for unresectable cholangiocarcinoma[J].Radiother Oncol,2010,94(1):47-52.DOI:10.1016/j.radonc.2009.11.004.
[11] Mahadevan A,Dagoglu N,Mancias J,et al. Stereotactic Body Radiotherapy (SBRT) for intrahepatic and hilar cholangiocarcinoma[J].J Cancer,2015,6(11):1099-1104.DOI:10.7150/jca.13032.
[12] Jung DH,Kim MS,Cho CK,et al. Outcomes of stereotactic body radiotherapy for unresectable primary or recurrent cholangiocarcinoma[J].Radiat Oncol J,2014,32(3):163-169.DOI:10.3857/roj.2014.32.3.163.
[13] Dang YZ,Huang SG,Lu WL,et al. Curative effect of stereotactic body radiotherapy on hepatic hilar carcinoma[J].Mol Clin Oncol,2014,2(6):1135-1138.DOI:10.3892/mco.2014.395.
[14] Eriguchi T,Takeda A,Sanuki N,et al. Acceptable toxicity after stereotactic body radiation therapy for liver tumors adjacent to the central biliary system[J].Int J Radiat Oncol Biol Phys,2013,85(4):1006-1011.DOI:10.1016/j.ijrobp.2012.09.012.
[15] Tao RD,Krishnan S,Bhosale PR,et al. Ablative radiotherapy doses lead to a substantial prolongation of survival in patients with inoperable intrahepatic cholangiocarcinoma:a retrospective dose response analysis[J].J Clin Oncol,2016,34(3):219-226.DOI:10.1200/JCO.2015.61.3778.
[16] Méndez Romero A,de Man RA.Stereotactic body radiation therapy for primary and metastatic liver tumors:from technological evolution to improved patient care[J].Best Pract Res Clin Gastroenterol,2016,30(4):603-616.DOI:10.1016/j.bpg.2016.06.003.
[17] Case RB,Moseley DJ,Sonke JJ,et al. Interfraction and intrafraction changes in amplitude of breathing motion in stereotactic liver radiotherapy[J].Int J Radiat Oncol Biol Phys,2010,77(3):918-925.DOI:10.1016/j.ijrobp.2009.09.008.
[18] Wagman R,Yorke E,Ford E,et al. Respiratory gating for liver tumors:use in dose escalation[J].Int J Radiat Oncol Biol Phys,2003,55(3):659-668.DOI:10.1016/S0360-3016(02)03941-X.
[19] Velec M,Moseley JL,Dawson LA,et al. Dose escalated liver stereotactic body radiation therapy at the mean respiratory position[J].Int J Radiat Oncol Biol Phys,2014,89(5):1121-1128.DOI:10.1016/j.ijrobp.2014.04.051.
[20] Yorke E,Xiong Y,Han Q,et al. Kilovoltage imaging of implanted fiducials to monitor intrafraction motion with abdominal compression during stereotactic body radiation therapy for gastrointestinal tumors[J].Int J Radiat Oncol Biol Phys,2016,95(3):1042-1049.DOI:10.1016/j.ijrobp.2015.11.018.